

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: Tissue Therapies Limited

主要联系人姓名: Brian Ziegelaar

主要联系人职务: 国际产品经理

公司网址: www.tissuetherapies.com

公司地址: Level 19, 179 Turbot Street, Brisbane QLD 4000

公司已上市

公司简介

Tissue Therapies 有限公司是一家保健生物技术公司, 专门开发生产可有效帮助伤口愈合的蛋白质。Tissue Therapies 为医师和消费者量身定制, 致力于确保患者和其照护者都获得更好的治疗和成效。Tissue Therapies 有限公司股票在澳大利亚、柏林、法兰克福证券交易所上市交易。

关键技术或领先技术

VitroGro®细胞外基质

人体中的玻连蛋白是人体最粘的蛋白中的一种, 这天然的粘性使其在伤口愈合的初始阶段有着关键作用。伤口愈合被认为是一个基于依附的过程。玻连蛋白的粘性使其粘附在伤口处, 与其他愈合伤口的蛋白相结合成一种基质, 以供皮肤细胞依附。在生长因子 (如 IGF-1) 的协助下, 已完成依附的细胞可以开始进行细胞迁移和增殖, 以促进伤口愈合。

在慢性伤口中, 这种基于细胞依附、移动、增殖的愈合过程由于伤口长时间的发炎而导致恢复受限。长时间的发炎破坏细胞附着所需的蛋白基质, 抑制恢复并延缓或中止伤口愈合过程。通过用促进愈合的基质替换已受损的基质, 慢性伤口便可以重新开始愈合。

VitroGro®细胞外基质是一种新型人造基质蛋白, 其含有一定量的玻连蛋白, 可有效的在伤口床附着其他蛋白, 并为皮肤细胞依附提供依附点。VitroGro®还含有生长因子 IGF-I, 可帮助已依附的细胞进行迁移和增殖。该设计针对慢性伤口引起的恢复停滞, 通过替换掉慢性伤口受损的基质来为细胞依附提供依附点, 重新激活细胞依附、迁移、增殖的伤口愈合过程。

类别

设备类:伤口护理

关键技术或领先技术

VitroGro®细胞外基质目前正在进行欧洲的上市监管审查。

合作机会

Tissue Therapies 有限公司随时欢迎合作和投资洽谈。

Directory of Australian medtech companies



COMPANY DETAILS

Company name: Tissue Therapies Limited

Key contact name: Brian Ziegelaar

Job title of key contact: International Product Manager

Company website address: www.tissuetherapies.com

Company address: Level 19, 179 Turbot Street, Brisbane QLD 4000

The company is Listed.

ABOUT THE COMPANY

Tissue Therapies Limited is a health biotechnology company that develops and manufactures proteins that efficiently heal wounds. At Tissue Therapies we strive to be the partner of both the clinician and payer to secure better outcomes for patients and their carers. Tissue Therapies Limited shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

KEY OR LEAD TECHNOLOGY

VitroGro® ECM

Native vitronectin one of the bodies most adhesive proteins and this natural 'stickiness' helps it play a key role in the initial stages of wound healing. Wound healing is said to be an "anchorage dependent" process. The sticky nature of vitronectin allows it to adhere to the wound bed and combine with other wound healing proteins to form a matrix to which skin cells can attach. With the support of growth factors such as IGF-I, these anchored cells can initiate the migration and proliferation needed to close the wound.

In chronic wounds this anchorage dependent proliferation and migration is compromised because the wound is stalled in a prolonged inflammatory phase. Prolonged inflammation damages the protein matrix required for cell attachment and inhibits its restoration delaying or halting healing. Healing can be reinstated in chronic wounds by replacing the damaged matrix with a substitute that promotes healing.

VitroGro® ECM is a novel synthetic matrix protein that contains a portion of the vitronectin protein that is specifically active in adhering to other proteins in the wound bed and providing sites for the attachment of skin cells. VitroGro® ECM also contains the growth factor IGF-I that helps support the migration and proliferation of attached cells. This design targets the stages of healing at which chronic wounds stall, promoting healing by replacing the damaged scaffold of chronic wounds, providing sites for cell attachment, which restores the anchorage dependent migration and proliferation required for healing.

Category

Devices: Wound care

Point of development of key or lead technology

VitroGro® ECM is currently under regulatory review for sale in Europe.

OPPORTUNITIES SOUGHT

Tissue Therapies Limited is always open to partnership and investment discussions.